Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours Β· Estimated delivery Aug 13 - Aug 18
Distinguishing between medication effects, weight loss consequences, and coincidental hormonal changes requires careful clinical evaluation and appropriate laboratory testing
You Have a BMI of 30 or Higher The FDA has approved GLP-1 medications for individuals with a BMI (Body Mass Index) of 30 or higher, which is classified as obese
The TRIUMPH-1 results, released May 21, 2026, are topline data that have not yet been peer-reviewed or published in a medical journal
Cold packs added on request
This injectable form was first approved by the FDA in December 2017 for the treatment of type 2 diabetes, reducing the risk of major cardiovascular events in patients with type 2 diabetes and cardiovascular disease, and reducing the risk of kidney disease progression and cardiovascular death in patients with type 2 diabetes and chronic kidney disease
RELATED STORY | Hims and Hers likely to stop selling cheaper versions of GLP-1 medications The drugs have been in short supply since 2022, soon after the FDA approved Wegovy for weight loss purposes
US$ 22.47
US$ 23.16
US$ 27.12
![D-Asp15]-Tirzepatide](https://www.daicelpharmastandards.com/wp-content/uploads/2024/02/dcti-d-317.png)
US$ 21.83
US$ 20.21
US$ 21.72
